Physician profile
Narinder Dawar
NPI 1750651238
$4,283.11
in general payments reported to CMS, 2019-2025
24 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $385 · 2021: $457 · 2022: $673 · 2023: $574 · 2024: $676 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.90 | 2022-2025 | Teflaro, Avycaz, Dalvance |
| Janssen Pharmaceuticals, INC | $394.66 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $361.91 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals Lp | $339.34 | 2021-2024 | Lokelma, Breztri |
| Regeneron Healthcare Solutions, INC. | $249.27 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $215.44 | 2022-2024 | Nuplazid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.55 | 2019-2023 | Jardiance |
| Pfizer INC. | $175.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $172.02 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $137.63 | 2019-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2023 | |
| Novo Nordisk INC | $124.96 | 2019 | |
| Amgen INC. | $124.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $124.77 | 2020 | |
| Esperion Therapeutics, INC. | $124.59 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $120.00 | 2022 | |
| Lilly USA, LLC | $90.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $65.27 | 2025 | |
| Avanir Pharmaceuticals, INC. | $60.64 | 2019 | |
| Mylan Specialty L.P. | $42.04 | 2020-2022 | |
| Allergan, INC. | $27.78 | 2019 | |
| Ucb, INC. | $24.80 | 2024 | Briviact |
| Cumberland Pharmaceuticals, INC. | $17.56 | 2025 | Caldolor |
| Smith+Nephew, INC. | $15.39 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Dawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.